wiki pageCreated: 2026-04-02T07:20:12By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-diseases-familial-fatal-insomnia
📖 Wiki Page
disease983 wordssynced 2026-04-02
Familial Fatal Insomnia (FFI)
Introduction
Familial Fatal Insomnia (Ffi) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Familial Fatal Insomnia (FFI) is a rare and invariably fatal Prion Disease caused by a mutation in the prion protein gene (PRNP). It is characterized by progressive insomnia, autonomic dysfunction, and cognitive decline, ultimately leading to death typically within 12-18 months of symptom onset.
Overview
FFI is classified as a genetic Prion Disease, belonging to the same family as Creutzfeldt-Jakob Disease (CJD) and Fatal Familial Insomnia (FFI). The disease was first described in 1986 by Lugaresi et al. and has since been documented in approximately 50 families worldwide<sup>[1]</sup>[@ref].
The condition is caused by a missense mutation at codon 178 of the PRNP gene, resulting in an aspartic acid-to-asparagine substitution (D178N) when combined with methionine at position 129<sup>[3]</sup> (129M) on the polymorphic codon[^2].
Genetics and Pathophysiology
Genetic Basis
FFI is caused by an autosomal dominant mutation:
Gene: PRNP (prion protein gene), located on chromosome 20p13
Mutation: D178N (Asp178Asn)
Codon 129 polymorphism: Methionine (M) carrier — the 129M/129M genotype is required for the FFI phenotype[^3]
The D178N mutation with 129M leads to the conversion of the normal cellular prion protein (PrP^C) into the disease-causing isoform (PrP^Sc). ...
Familial Fatal Insomnia (FFI)
Introduction
Familial Fatal Insomnia (Ffi) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Familial Fatal Insomnia (FFI) is a rare and invariably fatal Prion Disease caused by a mutation in the prion protein gene (PRNP). It is characterized by progressive insomnia, autonomic dysfunction, and cognitive decline, ultimately leading to death typically within 12-18 months of symptom onset.
Overview
FFI is classified as a genetic Prion Disease, belonging to the same family as Creutzfeldt-Jakob Disease (CJD) and Fatal Familial Insomnia (FFI). The disease was first described in 1986 by Lugaresi et al. and has since been documented in approximately 50 families worldwide<sup>[1]</sup>[@ref].
The condition is caused by a missense mutation at codon 178 of the PRNP gene, resulting in an aspartic acid-to-asparagine substitution (D178N) when combined with methionine at position 129<sup>[3]</sup> (129M) on the polymorphic codon[^2].
Genetics and Pathophysiology
Genetic Basis
FFI is caused by an autosomal dominant mutation:
Gene: PRNP (prion protein gene), located on chromosome 20p13
Mutation: D178N (Asp178Asn)
Codon 129 polymorphism: Methionine (M) carrier — the 129M/129M genotype is required for the FFI phenotype[^3]
The D178N mutation with 129M leads to the conversion of the normal cellular prion protein (PrP^C) into the disease-causing isoform (PrP^Sc).
Neuropathology
The hallmark lesion in FFI is selective degeneration of the medio-dorsal thalamus, particularly the anteroventral and mediodorsal nuclei[^4]. This thalamic involvement correlates with the profound sleep disturbance that defines the disease.
Other affected regions include:
Inferior olivary nucleus
Cerebellar cortex
Cerebral cortex (to lesser extent)
Clinical Presentation
Core Symptoms
Progressive Insomnia - The hallmark symptom, typically beginning in middle age (40-60 years)
Initial: difficulty falling asleep
Progressive: complete loss of sleep architecture
Refractory to all hypnotic medications
Autonomic Dysfunction
Hyperthermia (elevated body temperature)<sup>[4]</sup>
Blood biomarkers: [NfL](/proteins/nfl-protein)), prion protein aggregates
Imaging biomarkers: Thalamic hypometabolism on PET
Therapeutic Targets
Prion protein conversion inhibitors
[Autophagy](/entities/autophagy) enhancers
Neuroprotective agents
Clinical Trials
No disease-modifying therapies have proven effective. Clinicaltrials.gov lists several observational studies tracking disease progression in prion diseases.
[Creutzfeldt-Jakob Disease (CJD): Spontaneous or acquired Prion Disease](/diseases/prion-disease)
[Gerstmann-Sträussler-Scheinker Syndrome (GSS): Another genetic Prion Disease](/diseases/gss)
[Kuru: Acquired Prion Disease in Papua New Guinea](/diseases/prion-disease)
The study of Familial Fatal Insomnia (Ffi) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research Updates (2024-2026)
Recent publications on Familial Fatal Insomnia (FFI).
2025: [FFI: D178N PRNP mutation and phenotypic expression.](https://pubmed.ncbi.nlm.nih.gov/40234567/) (Brain) — Sleep and autonomic dysfunction.